Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

NCT02603562 is registered in ClinicalTrials.gov with aTyr Pharma, Inc. as lead sponsor.

NCT NCT02603562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02603562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Lead sponsor
aTyr Pharma, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 30, 2016
Completion date
December 12, 2016
Enrollment
8 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

facioscapulohumeral muscular dystrophy (fshd)